Amino acid transporter-based drug development for cerebral creatine deficiency syndrome
| Project/Area Number |
16K15153
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
立川 正憲 東北大学, 薬学研究科, 准教授 (00401810)
吉田 将人 東北大学, 薬学研究科, 助教 (80511906)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 血液脳関門 / クレアチントランスポーター / クレアチン脳欠乏症 / 脳クレアチン欠乏症 / 薬学 / 脳・神経 / 生体機能利用 |
|---|
| Outline of Final Research Achievements |
The purpose of the present study was to establish the basis of creatine prodrug therapy for cerebral creatine deficiency with creatine transporter (CRT/SLC6A8) defect. Protein expression of transporters as the potent brain drug delivery pathways was clarified in developing rat blood-brain barrier based on quantitative targeted absolute proteomics. The patient-derived fibroblasts exhibited the cellular transport of the chemically synthesized creatine prodrug followed by the creatine generation.
|
Report
(3 results)
Research Products
(4 results)
